Cynthia L. Fisher

Cynthia L. Fisher

Auto-generated profile, based on publicly available information

Cynthia L. Fisher

Lymphocyte Development Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2010 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
DLDavid Landeira
David Landeira
SSStephan Sauer
Stephan Sauer
RPRaymond Poot
Raymond Poot
MDMaria Dvorkina
Maria Dvorkina
Luca MazzarellaLuca Mazzarella
Luca Mazzarella
AFAmanda G. Fisher
Amanda G. Fisher

9 May 2016 in Genome Research
Verified
Journal Article
Open access
PDF file
MBManuel Beltran
Manuel Beltran
CYChristopher M. Yates
Christopher M. Yates
LSLenka Skalska
Lenka Skalska
MDMarcus Dawson
Marcus Dawson
FRFilipa P. Reis
Filipa P. Reis
RJRichard G. Jenner
Richard G. Jenner
Polycomb repressive complex 2 (PRC2) modifies chromatin to maintain genes in a repressed state during development. PRC2 is primarily associated with CpG islands at repressed genes and also possesses RNA binding activity. However, the RNAs that bind PRC2 in cells, the subunits that mediate these interactions, and the role of RNA in PRC2 recruitment to chromatin all remain unclear. By performing iCLIP for PRC2 in comparison with other RNA binding proteins, we show here that PRC2 binds nascent RNA at essentially all active genes. Although interacting with RNA promiscuously, PRC2 binding is enriched at specific locations within RNAs, primarily exon–intron boundaries and the 3′ UTR. Deletion of other PRC2 subunits reveals that SUZ12 is sufficient to establish this RNA binding profile. Contrary to prevailing models, we also demonstrate that the interaction of PRC2 with RNA or chromatin is mutually antagonistic in cells and in vitro. RNA degradation in cells triggers PRC2 recruitment to CpG islands at active genes. Correspondingly, the release of PRC2 from chromatin in cells increases RNA binding. Consistent with this, RNA and nucleosomes compete for PRC2 binding in vitro. We propose that RNA prevents PRC2 recruitment to chromatin at active genes and that mutual antagonism between RNA and chromatin underlies the pattern of PRC2 chromatin association across the genome.

1 April 2011 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
CFCynthia L Fisher
Cynthia L Fisher
AFAmanda G Fisher
Amanda G Fisher

20 April 2014 in Nature Materials
Verified
Journal Article
Closed access
PDF file
SPStefano Pagliara
Stefano Pagliara
FKFranze Kristian
Franze Kristian
CMCrystal R. McClain
Crystal R. McClain
GWGeorge W. Wylde
George W. Wylde
CFCynthia L. Fisher
Cynthia L. Fisher
KCKevin J. Chalut
Kevin J. Chalut

7 January 2010 in Blood
Verified
Journal Article
Closed access
PDF file
CFCynthia L. Fisher
Cynthia L. Fisher
NPNicolas Pineault
Nicolas Pineault
CBChristy Brookes
Christy Brookes
CHCheryl D. Helgason
Cheryl D. Helgason
HOHideaki Ohta
Hideaki Ohta
HBHugh W. Brock
Hugh W. Brock
The Additional sex combs like 1 (Asxl1) gene is 1 of 3 mammalian homologs of the Additional sex combs (Asx) gene of Drosophila. Asx is unusual because it is required to maintain both activation and silencing of Hox genes in flies and mice. Asxl proteins are characterized by an amino terminal homology domain, by interaction domains for nuclear receptors, and by a C-terminal plant homeodomain protein-protein interaction domain. A recent study of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) revealed a high incidence of truncation mutations that would delete the PHD domain of ASXL1. Here, we show that Asxl1 is expressed in all hematopoietic cell fractions analyzed. Asxl1 knockout mice exhibit defects in frequency of differentiation of lymphoid and myeloid progenitors, but not in multipotent progenitors. We do not detect effects on hematopoietic stem cells, or in peripheral blood. Notably, we do not detect severe myelodysplastic phenotypes or leukemia in this loss-of-function model. We conclude that Asxl1 is needed for normal hematopoiesis. The mild phenotypes observed may be because other Asxl genes have redundant function with Asxl1, or alternatively, MDS or oncogenic phenotypes may result from gain-of-function Asxl mutations caused by genomic amplification, gene fusion, or truncation of Asxl1.

9 February 2005 in Developmental Dynamics
Verified
Journal Article
Closed access
PDF file
HBHugh W. Brock
Hugh W. Brock
CFCynthia L. Fisher
Cynthia L. Fisher